

CITATION REPORT

List of articles citing

Safety, dosing, and pharmaceutical quality for studies that evaluate medicinal products (including biological products) in neonates

DOI: 10.1038/pr.2016.221
Pediatric Research, 2017, 81, 692-711.

Source: <https://exaly.com/paper-pdf/66137528/citation-report.pdf>

Version: 2024-04-25

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
67	Newborns still lack drug data to guide therapy. <i>British Journal of Clinical Pharmacology</i> , 2016 , 82, 1410-1418	3.1	7
66	The future of pediatric research: European perspective. <i>Pediatric Research</i> , 2017 , 81, 138-139	3.2	3
65	Frameworks for Evaluating Medicines in Children. <i>Clinical Therapeutics</i> , 2017 , 39, 1949-1958	3.5	0
64	Avoid Drug Incompatibilities: Clinical Context in Neonatal Intensive Care Unit (NICU). <i>Pharmaceutical Technology in Hospital Pharmacy</i> , 2017 , 2,	0.5	2
63	Better medicines for neonates: Improving medicine development, testing, and prescribing. <i>Early Human Development</i> , 2017 , 114, 22-25	2.2	6
62	Development of Drug Therapies for Newborns and Children: The Scientific and Regulatory Imperatives. <i>Pediatric Clinics of North America</i> , 2017 , 64, 1185-1196	3.6	17
61	Drug evaluation studies in neonates: how to overcome the current limitations. <i>Expert Review of Clinical Pharmacology</i> , 2018 , 11, 387-396	3.8	8
60	Useful pharmacodynamic endpoints in children: selection, measurement, and next steps. <i>Pediatric Research</i> , 2018 , 83, 1095-1103	3.2	11
59	Drug metabolism in early infancy: opioids as an illustration. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2018 , 14, 287-301	5.5	13
58	Challenges and Opportunities in the Development of Medical Therapies for Pediatric Populations and the Role of Extrapolation. <i>Clinical Pharmacology and Therapeutics</i> , 2018 , 103, 419-433	6.1	22
57	A directory for neonatal intensive care: potential for facilitating network-based research in neonatology. <i>Journal of Perinatology</i> , 2018 , 38, 954-958	3.1	1
56	Response biomarkers in neonatal intervention studies. <i>Pediatric Research</i> , 2018 , 83, 425-430	3.2	2
55	The Need for Pediatric Drug Development. <i>Journal of Pediatrics</i> , 2018 , 192, 13-21	3.6	33
54	Development of one paediatric and one neonatal formulary list in hospital settings. <i>British Journal of Clinical Pharmacology</i> , 2018 , 84, 349-357	3.8	2
53	Collaboration in Regulatory Science to Facilitate Therapeutic Development for Neonates. <i>Current Pharmaceutical Design</i> , 2017 , 23, 5801-5804	3.3	0
52	Developmental Pharmacology - Special Issues During Childhood and Adolescence. <i>Drug Research</i> , 2018 , 68, S10-S11	1.8	1
51	Sharing Data to Accelerate Medicine Development and Improve Neonatal Care: Data Standards and Harmonized Definitions. <i>Journal of Pediatrics</i> , 2018 , 203, 437-441.e1	3.6	10

50	Rational Use of Medicines in Neonates: Current Observations, Areas for Research and Perspectives. <i>Healthcare (Switzerland)</i> , 2018 , 6,	3.4	5
49	Quantitative Systems Pharmacology Modeling of Acid Sphingomyelinase Deficiency and the Enzyme Replacement Therapy Olipudase Alfa Is an Innovative Tool for Linking Pathophysiology and Pharmacology. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2018 , 7, 442-452	4.5	12
48	Neonates are not just little children and need more finesse in dosing of antibiotics. <i>Acta Clinica Belgica</i> , 2019 , 74, 157-163	1.8	5
47	Pharmacokinetic modelling and Bayesian estimation-assisted decision tools to optimize vancomycin dosage in neonates: only one piece of the puzzle. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2019 , 15, 735-749	5.5	8
46	Pediatric Age Groups and Approach to Studies. <i>Therapeutic Innovation and Regulatory Science</i> , 2019 , 53, 584-589	1.2	5
45	Comparison of immune system development in nonclinical species and humans: Closing information gaps for immunotoxicity testing and human translatability. <i>Reproductive Toxicology</i> , 2019 , 89, 178-188	3.4	9
44	Making Medicines Baby Size: The Challenges in Bridging the Formulation Gap in Neonatal Medicine. <i>International Journal of Molecular Sciences</i> , 2019 , 20,	6.3	16
43	Drug related problems in the neonatal intensive care unit: incidence, characterization and clinical relevance. <i>BMC Pediatrics</i> , 2019 , 19, 134	2.6	4
42	Commentary on the EMA Reflection Paper on the use of extrapolation in the development of medicines for paediatrics. <i>British Journal of Clinical Pharmacology</i> , 2019 , 85, 659-668	3.8	18
41	Challenges in Designing Clinical Trials to Test New Drugs in the Pregnant Woman and Fetus. <i>Clinics in Perinatology</i> , 2019 , 46, 399-416	2.8	4
40	Recommendations for the design of therapeutic trials for neonatal seizures. <i>Pediatric Research</i> , 2019 , 85, 943-954	3.2	28
39	Tiny and Forgotten: A Call for Focused Neonatal Policy Reform. <i>Therapeutic Innovation and Regulatory Science</i> , 2019 , 53, 615-617	1.2	6
38	Research on medication use in the neonatal intensive care unit. <i>Expert Review of Clinical Pharmacology</i> , 2019 , 12, 343-353	3.8	7
37	Ontogeny of ADME Processes during Postnatal Development in Man and Preclinical Species: A Comprehensive Review. <i>Drug Metabolism and Disposition</i> , 2019 , 47, 295	4	5
36	Rational Use of Antibiotics in Neonates: Still in Search of Tailored Tools. <i>Healthcare (Switzerland)</i> , 2019 , 7,	3.4	8
35	Development of a neonatal adverse event severity scale through a Delphi consensus approach. <i>Archives of Disease in Childhood</i> , 2019 , 104, 1167-1173	2.2	21
34	Physiologically based pharmacokinetic (PBPK) modeling and simulation in neonatal drug development: how clinicians can contribute. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2019 , 15, 25-34	5.5	15
33	Renal Clearance in Newborns and Infants: Predictive Performance of Population-Based Modeling for Drug Development. <i>Clinical Pharmacology and Therapeutics</i> , 2019 , 105, 1462-1470	6.1	21

32	A phase 1 healthy male volunteer single escalating dose study of the pharmacokinetics and pharmacodynamics of risdiplam (RG7916, RO7034067), a SMN2 splicing modifier. <i>British Journal of Clinical Pharmacology</i> , 2019 , 85, 181-193	3.8	51
31	Preterm Physiologically Based Pharmacokinetic Model. Part II: Applications of the Model to Predict Drug Pharmacokinetics in the Preterm Population. <i>Clinical Pharmacokinetics</i> , 2020 , 59, 501-518	6.2	22
30	Standardizing Safety Assessment and Reporting for Neonatal Clinical Trials. <i>Journal of Pediatrics</i> , 2020 , 219, 243-249.e1	3.6	8
29	Respiratory medication use in extremely premature (. <i>Pediatric Pulmonology</i> , 2020 , 55, 360-368	3.5	12
28	Approaches to Dose Finding in Neonates, Illustrating the Variability between Neonatal Drug Development Programs. <i>Pharmaceutics</i> , 2020 , 12,	6.4	11
27	New Ways to Measure the Effect of Pharmacotherapy in Newborn Infants: Feasible or Not That Much?. <i>Neonatology</i> , 2020 , 117, 436-437	4	2
26	Renal Precision Medicine in Neonates and Acute Kidney Injury: How to Convert a Cloud of Creatinine Observations to Support Clinical Decisions. <i>Frontiers in Pediatrics</i> , 2020 , 8, 366	3.4	15
25	Stem Cells: The Magic Cure?. <i>Pediatric and Adolescent Medicine</i> , 2020 , 184-197	0.4	
24	How to introduce MSC-based therapy for the developing lung safely into clinical care?. <i>Pediatric Research</i> , 2020 , 88, 365-368	3.2	4
23	Cangrelor PK/PD analysis in post-operative neonatal cardiac patients at risk for thrombosis. <i>Journal of Thrombosis and Haemostasis</i> , 2021 , 19, 202-211	15.4	2
22	Amikacin or Vancomycin Exposure Alters the Postnatal Serum Creatinine Dynamics in Extreme Low Birth Weight Neonates. <i>International Journal of Environmental Research and Public Health</i> , 2021 , 18,	4.6	1
21	Neonatology. 2021 , 263-269		
20	The conect4children (c4c) Consortium: Potential for Improving European Clinical Research into Medicines for Children. <i>Pharmaceutical Medicine</i> , 2021 , 35, 71-79	2.3	4
19	Editorial: Precision Medicine in Neonates. <i>Frontiers in Pediatrics</i> , 2021 , 9, 702760	3.4	0
18	Model-Informed Pediatric Drug Development: Application of Pharmacometrics to Define the Right Dose for Children. <i>Journal of Clinical Pharmacology</i> , 2021 , 61 Suppl 1, S52-S59	2.9	0
17	Dose-Related Adverse Drug Events in Neonates: Recognition and Assessment. <i>Journal of Clinical Pharmacology</i> , 2021 , 61 Suppl 1, S152-S160	2.9	0
16	Population Model of Serum Creatinine as Time-Dependent Covariate in Neonates. <i>AAPS Journal</i> , 2021 , 23, 86	3.7	0
15	The European Medicines Agency Experience With Pediatric Dose Selection. <i>Journal of Clinical Pharmacology</i> , 2021 , 61 Suppl 1, S22-S27	2.9	0

14	Considerations for Drug Dosing in Premature Infants. <i>Journal of Clinical Pharmacology</i> , 2021 , 61 Suppl 1, S141-S151	2.9	2
13	Application of Physiologically Based Pharmacokinetic-Pharmacodynamic Modeling in Preterm Neonates to Guide Gentamicin Dosing Decisions and Predict Antibacterial Effect. <i>Journal of Clinical Pharmacology</i> , 2021 , 61, 1356-1365	2.9	2
12	Adaptive Focused Acoustics For Nanosuspensions to Enable Pharmacology Assessment of Poorly Soluble Molecules in Lead Optimization. <i>Journal of Pharmaceutical Sciences</i> , 2021 , 110, 2728-2732	3.9	
11	Clinical Research in Neonates: Redesigning the Informed Consent Process in the Digital Era. <i>Frontiers in Pediatrics</i> , 2021 , 9, 724431	3.4	1
10	Why are certain age bands used for children in paediatric studies of medicines?. <i>Archives of Disease in Childhood</i> , 2021 , 106, 631-635	2.2	0
9	The Neonatal and Juvenile Pig in Pediatric Drug Discovery and Development. <i>Pharmaceutics</i> , 2020 , 13,	6.4	9
8	Challenges and opportunities for improving access to approved neonatal drugs and devices.. <i>Journal of Perinatology</i> , 2022 ,	3.1	0
7	Broadly Engaged Team Science in Neonatal Research. 2022 , 19-25		
6	From immature pharmacotherapy towards pharmacotherapy of the immature.. <i>Seminars in Fetal and Neonatal Medicine</i> , 2022 , 101327	3.7	0
5	QTc Intervals Are Prolonged in Late Preterm and Term Neonates during Therapeutic Hypothermia but Normalize Afterwards.. <i>Children</i> , 2021 , 8,	2.8	
4	Current and future physiologically based pharmacokinetic (PBPK) modeling approaches to optimize pharmacotherapy in preterm neonates. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 1-12	5.5	0
3	Establishing Evidence-Based Pharmacologic Treatments for Neonatal Abstinence Syndrome: A Retrospective Case Study. <i>Journal of Clinical and Translational Science</i> , 1-25	0.4	
2	Développement des médicaments en pédiatrie : défis existants et recommandations. 2022 ,		0
1	Paediatric drug development and evaluation: Existing challenges and recommendations. 2022 ,		0